Economic Times -- Frustrated with patent challenges, Swiss-pharma giant Novartis has put its research and development (R&D) activities in India on the back burner, its CEO Daniel Vasella said. Mr Vasella, who was in town to attend the Pepsico board meet, said the intellectual property (IP) protection was not up to the mark in India. “In principle you can discover in India, you can do research. There has been some progress on the protection of intellectual property but its not up to the standard that I would expect to make an investment into discovery led research,” Mr Vasella said.
